Advances in DLBCL Treatment Novotech’s report also highlights breakthroughs in DLBCL treatment, moving beyond traditional chemotherapy to explore new therapeutic options: Ongoing efforts to ...
New York-based oncology analytics company, COTA is set to present data showing that older patients with Diffuse Large B-cell Lymphoma (DLBCL) who initiate treatment immediately after diagnosis may ...
Panelists discuss how a diagnosis of diffuse large B-cell lymphoma or follicular lymphoma affects patients physically and emotionally and how these challenges shape their treatment journey and overall ...
ADC Therapeutics (NYSE:ADCT) is continuing to make strides with the advancement of its drug ZYNLONTA [Loncastuximab Tesirine-lpyl] for the treatment of patients with DLBCL. Specifically ...
The 5-year results of the POLARIX study show a continued progression-free survival benefit for patients with diffuse large ...
About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease ...
1 The study aims to evaluate the ability to utilize Foresight CLARITY™ MRD detection to enable real-time treatment optimization for patients with diffuse large B-cell lymphoma (DLBCL).
Ongoing efforts to personalize DLBCL treatment through genomic profiling and molecular diagnostics are expected to yield more precise and effective treatment strategies. In combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback